The COPD Foundation has partnered with Renovion on development of Renovion's ARINA-1 nebulized glutathione / bicarbonate / ascorbic acid for the treatment of COPD and non-cystic fibrosis bronchiectasis, the foundation said. ARINA-1, which is delivered via the PARI eFlow nebulizer system, received orphan drug designation from the FDA for the treatment of lung … [Read more...] about COPD Foundation partners with Renovion for development of inhaled mucolytic
Medical
Phase 2 trial of inhaled Ampion for COVID-19 gets approval from Indian authorities
According to Ampio Pharmaceuticals, the Drugs Controller General of India (DCGI) has approved the protocol for AP-019 Phase 2 trial of the company's inhaled Ampion biologic for the treatment of respiratory distress caused by COVID-19. Ampio announced in June 2021 that it had initiated the Phase 2 AP-019 clinical trial in the US and noted that the FDA had approved … [Read more...] about Phase 2 trial of inhaled Ampion for COVID-19 gets approval from Indian authorities
GSK says it is evaluating new MDI propellant as part of commitment to reducing greenhouse gas emissions
GlaxoSmithKline has announced an initiative to evaluate a new lower global warming potential propellant for its metered dose inhalers as part of an effort to reach net zero carbon emissions. According to GSK, its Ventolin albuterol (salbutamol) MDIs for the rescue treatment of asthma account for 45% of the company's current carbon emissions, and the company expects … [Read more...] about GSK says it is evaluating new MDI propellant as part of commitment to reducing greenhouse gas emissions
Virpax to develop intranasal CBD for the treatment of epilepsy
Virpax says that it has acquired exclusive worldwide rights to Nanomerics's molecular envelope technology (MET) for use with Virpax's VRP324 intranasal dry powder cannabidiol (CBD) for the treatment of epilepsy. According to Virpax, Nanomerics is currently conducting preclinical studies of VRP324, which Virpax plans to develop for the treatment of seizures due to … [Read more...] about Virpax to develop intranasal CBD for the treatment of epilepsy
Neurelis initiates Phase 1/2a study of Valtoco nasal spray in pediatric epilepsy patients
Neurelis said that it has initiated the Stellina Phase 1/2a trial of Valtoco diazepam nasal spray in epilepsy patients between the ages of 2 and 5. The news comes almost exactly one year after the company announced plans for the pediatric trial and a future sNDA submission. Valtoco has been approved in the US for the treatment of seizure clusters in patients 6 years … [Read more...] about Neurelis initiates Phase 1/2a study of Valtoco nasal spray in pediatric epilepsy patients
Kinaset initiates Phase 1b trial of its KN-002 dry powder JAK inhibitor
Kinaset Therapeutics said that dosing is underway in a Phase 1b SAD/MAD study of its KN-002 dry powder JAK inhibitor, which it is developing for the treatment of asthma and COPD. The trial is expected to enroll 48 healthy volunteers in the single ascending dose portion of the study and 32 asthma patients in the multiple ascending dose part of the study. The … [Read more...] about Kinaset initiates Phase 1b trial of its KN-002 dry powder JAK inhibitor
VistaGen initiates second Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder
VistaGen Therapeutics said that it has initiated the PALISADE-2 Phase 3 clinical trial of its PH94B aloradine nasal spray for the treatment of social anxiety disorder (SAD). The company initiated the PALISADE-1 trial of PH94B for SAD in May 2021. Topline results from that trial are expected in mid-2022, with results from the PALISADE-2 trial expected later that … [Read more...] about VistaGen initiates second Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder
Positive results for two Phase 3 studies of AstraZeneca’s PT027 albuterol/budesonide MDI
AstraZeneca has announced that the Phase 3 MANDALA and DENALI trials of PT027 albuterol (salbutamol)/budesonide MDI for the treatment of asthma both met their primary endpoints. The company has been co-developing PT027 with Avillion since 2018. The MANDALA trial, which enrolled 3,132 patients who were using inhaled corticosteroids for moderate to severe asthma, … [Read more...] about Positive results for two Phase 3 studies of AstraZeneca’s PT027 albuterol/budesonide MDI
Phase 3 trial of nebulized colistimethate sodium in patients with bronchiectasis and P. aeruginosa infection meets primary endpoint
Zambon has presented results from its Phase 3 PROMIS-I study of CMS colistimethate sodium powder demonstrating that a CMS solution delivered via the Philips I-neb nebulizer significantly reduced exacerbations in patients with non-cystic fibrosis bronchiectasis (NCFB) and chronic P. aeruginosa lung infections. The company received Fast Track and QIDP designations for … [Read more...] about Phase 3 trial of nebulized colistimethate sodium in patients with bronchiectasis and P. aeruginosa infection meets primary endpoint
Nocion Therapeutics announces Phase 2a trial of inhaled NTX-1175 charged sodium channel blocker for chronic cough
Nocion Therapeutics has dosed the first 10 subjects in a Phase 2a study of NOC-100, an inhaled formulation of its NTX-1175, a charged sodium channel blocker, the company said. Nocion is developing NTX-1175 for the treatment of chronic and acute cough, including cough resulting from COVID-19. According to the company, a Phase 1 study of inhaled NTX-1175 was completed … [Read more...] about Nocion Therapeutics announces Phase 2a trial of inhaled NTX-1175 charged sodium channel blocker for chronic cough